BOULDER, Colo. & BEVERLY, Mass.--(BUSINESS WIRE)--Enzymatics today launches the Archer™ Analysis Pipeline v3.0, it’s most advanced next-generation sequencing analysis platform to detect and characterize cancer-causing gene fusions and mutations from clinical sample types. The software combines cutting-edge analysis with an intuitive user interface enabling researchers to accurately call known or novel genomic alterations. This tool includes robust quality control systems, clear, detailed analytics, and interactive visualizations using JBrowse, resulting in accurate gene fusion and mutation reporting.
Help employers find you! Check out all the jobs and post your resume.
